Skip to main content

Table 2 Differences in the secondary outcome measure between the three trial arms

From: A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services

  SBNT (n = 26) PGS (n = 27) TAU (n = 30)
Item Baseline 3 months 12 months Baseline 3 months 12 months Baseline 3 months 12 months
Days abstinent from heroin, median (IQR) 15 (8,24) 18 (2,22) 17 (11,23) 18 (8,24) 18 (8,20) 18 (8,27) 20 (12,26) 23 (14,26) 25 (14,27)
LDQ total, median (IQR) 14 (8,17) 9 (5,16) 10 (6.6,16) 11 (5,15) 6 (5,12) 7 (4,10) 7 (2,13) 6 (3,12) 5 (2,13)
CORE
 Wellbeing, median (IQR) 2 (2,3) 2 (0.8,2.5) 2 (1.3,2.9) 2 (1,2) 1.6 (0.8,2.1) 1.5 (0.8,2) 2 (1,2) 1.3 (0.8,2) 1.5 (0.8,2.3)
 Symptoms, median (IQR) 2 (2,3) 2.1 (0.9,2.9) 2.4 (1.1,2.6) 2 (1,2) 1.3 (1,2.3) 1.5 (0.8,2) 2 (1,3) 1.3 (1,2.3) 1.6 (0.8,2.3)
 Functioning, median (IQR) 2 (2,3) 1.8 (1.2,2.6) 2.2 (1,2.7) 2 (1,2) 1.5 (1.1,2) 1.6 (0.8,2) 2 (1,2) 1.5 (1.1,2.1) 1.2 (0.8,1.9)
 SSQ total, median (IQR) 23 (19,26) 24 (22,28) 24 (19.5,27) 22 (18,25) 23 (19,24) 22 (20,26) 23 (20,27) 24 (20,28) 24 (22,27)
CEST
 Counselling rapport, median (IQR) 40 (38,43) 41 (38,43) 39 (35,46) 39 (36,42) 39 (38,42) 40 (39,42) 40 (39,43) 40 (39,44) 41 (40,48)
 Peer support, median (IQR) 32 (28,40) 30 (26,38) 30 (25,37) 30 (28,34) 30 (28,32) 30 (26,34) 32 (28,38) 32 (26,36) 36 (28,38)
 Treatment participation, median (IQR) 38 (33,39) 38 (36,39) 38 (31,42) 37 (35,38) 37 (35,38) 38 (35,40) 38 (34,41) 39 (37,42) 41 (40,47)
 Treatment satisfaction, median (IQR) 39 (35,41) 40 (36,43) 40 (35,40) 39 (37,41) 39 (37,41) 40 (36,42) 40 (39,43) 40 (39,44) 41 (40,47)
ISEL
 Appraisal, median (IQR) 16 (15,19) 17 (15,18) 18 (14,21) 16 (14,18) 18 (16,20) 18 (16,20) 16 (15,18) 18 (17,20) 18 (16,20)
 Belonging, median (IQR) 17 (14,19) 16 (14,18) 17 (14,19.5) 15 (13,17) 17 (15,19.5) 16 (14.5,19.5) 17 (15,18) 17 (16,20) 18 (15,21.5)
 Self-esteem, median (IQR) 14 (12,17) 14 (13,15) 13.5 (12,16.5) 14 (12,16) 15 (14,17) 15 (14,18) 16 (13,18) 15 (14,18) 15 (14,20)
 Tangible, median (IQR) 17 (13,19) 16 (14,19) 16 (14,19.5) 15 (14,19) 16 (15,19) 18 (14.5,19.5) 16 (14,18) 16 (14,17) 17.5 (15.5,21)
IPDA
 Index 1-network size (IQR) −0.42 (−0.66,0.24) 0.07 (−0.83,0.83) −0.29 (−0.74,1.01) − 0.18 (− 0.66,0.64) −0.14 (− 0.83,0.65) 0.12 (− 0.74,0.49) 0.24 (− 0.18,1.0) 0.07 (− 0.83,1.18) 0.12 (− 0.29,0.84)
 Index 2–daily network size (IQR) − 0.50 (−1.06,0.06) − 0.10 (− 0.58,0.37) −0.49 (− 0.76,0.06) −0.06 (− 0.50,1.18) −0.10 (− 0.58,0.37) −0.49 (− 0.49,0.61) −0.22 (− 0.50,0.06) −0.50 (− 0.50,0.62) 0.06 (− 0.49,0.61)
 Index 3-importance (IQR) −0.14 (− 0.65,0.62) 0.17 (− 0.33,0.75) −0.12 (− 0.58,0.67) −0.02 (− 1.08,1.25) −0.01 (− 0.89,0.94) −0.12 (− 0.62,0.38) −0.02 (− 0.86,1.25) −0.01 (− 0.43,0.75) 0.38 (− 0.12,1.14)
 Component 1: substance involvement (IQR) −0.40 (− 0.93,0.05) −0.35 (− 0.83,0.62) −0.28 (− 0.79,1.14) −0.06 (− 0.44,0.67) −0.24 (− 0.51,0.34) −0.37 (− 0.84,0.16) −0.24 (− 0.75,0.85) −0.49 (− 0.66,0.47) −0.07 (− 0.58,0.57)
 Component 2: general/treatment support (IQR) 0.14 (− 0.56,0.66) −0.04 (− 0.48,0.57) 0.24 (− 0.58,0.66) −0.49 (− 1.03, 0.30) −0.10 (− 0.50,0.74) −0.14 (− 0.83,0.43) 0.48 (− 0.35,1.02) 0.09 (− 0.17,0.77) 0.34 (− 0.30,0.82)
 Component 3-support for substance use (IQR) 0.16 (− 0.86,0.89) 0.25 (− 0.75,0.82) 0.48 (− 0.72,1.37) 0.34 (− 0.86,0.89) 0.08 (−0.75,0.68) − 0.51 (− 0.94,0.90) 0.02 (− 0.86,0.72) 0.07 (− 1.02,0.57) −0.51 (− 0.94,0.68)
RCQ-TV, median (IQR) 4.5 (4,7) 5 (4,6) 4 (4,7) 4 (3,5) 4 (3,5) 4 (4,6) 4.5 (4,6) 4 (4,6) 5 (4,7)